Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Blood Cells Mol Dis ; 69: 75-81, 2018 03.
Article in English | MEDLINE | ID: mdl-29032941

ABSTRACT

Developing red blood cells exhibit multiple, redundant systems for regulating and coordinating the uptake of iron, the synthesis of heme, and the formation of hemoglobin during terminal differentiation. We recently described the roles of poly rC-binding protein (PCBP1) and nuclear coactivator 4 (NCOA4) in mediating the flux of iron through ferritin in developing erythroid cells, with PCBP1, an iron chaperone, delivering iron to ferritin and NCOA4, an autophagic cargo receptor, directing ferritin to the lysosome for degradation and iron release. Ferritin iron flux is critical, as mice lacking these factors develop microcytic anemia. Here we report that these processes are regulated by cellular iron levels in a murine model of ex vivo terminal differentiation. PCBP1 delivers iron to ferritin via a direct protein-protein interaction. This interaction is developmentally regulated, enhanced by iron deprivation, and inhibited by iron excess, both in developing cells and in vitro. NCOA4 activity also exhibited developmental regulation and regulation by cellular iron levels. Excess iron uptake during differentiation triggered lysosomal degradation of NCOA4, which was dependent on the E3 ubiquitin ligase HERC2. Thus, developing red blood cells express a series of proteins that both mediate and regulate the flux of iron to the mitochondria.


Subject(s)
Erythroid Cells/cytology , Erythroid Cells/metabolism , Ferritins/metabolism , Heterogeneous-Nuclear Ribonucleoproteins/metabolism , Iron/metabolism , Nuclear Receptor Coactivators/metabolism , Carrier Proteins , Cell Line , DNA-Binding Proteins , Erythroid Precursor Cells/cytology , Erythroid Precursor Cells/metabolism , Erythropoiesis/genetics , Gene Expression , Heterogeneous-Nuclear Ribonucleoproteins/genetics , Humans , Lysosomes/metabolism , Models, Biological , Molecular Chaperones/metabolism , Nuclear Receptor Coactivators/genetics , RNA-Binding Proteins
2.
J Cereb Blood Flow Metab ; 38(3): 540-548, 2018 03.
Article in English | MEDLINE | ID: mdl-28350201

ABSTRACT

HFE (high iron) is an essential protein for regulating iron transport into cells. Mutations of the HFE gene result in loss of this regulation causing accumulation of iron within the cell. The mutated protein has been found increasingly in numerous neurodegenerative disorders in which increased levels of iron in the brain are reported. Additionally, evidence that these mutations are associated with elevated brain iron challenges the paradigm that the brain is protected by the blood-brain barrier. While much has been studied regarding the role of HFE in cellular iron uptake, it has remained unclear what role the protein plays in the transport of iron into the brain. We investigated regulation of iron transport into the brain using a mouse model with a mutation in the HFE gene. We demonstrated that the rate of radiolabeled iron (59Fe) uptake was similar between the two genotypes despite higher brain iron concentrations in the mutant. However, there were significant differences in iron uptake between males and females regardless of genotype. These data indicate that brain iron status is consistently maintained and tightly regulated at the level of the blood-brain barrier.


Subject(s)
Brain Chemistry/genetics , Hemochromatosis Protein/genetics , Iron/metabolism , Animals , Blood-Brain Barrier/growth & development , Blood-Brain Barrier/physiology , Brain/growth & development , Brain/physiology , Female , Gene Knock-In Techniques , Genetic Variation , Genotype , Iron Radioisotopes , Male , Mice , Microvessels/diagnostic imaging , Microvessels/metabolism , Mutation/genetics , Radiopharmaceuticals , Sex Characteristics
3.
Biochem Biophys Res Commun ; 494(1-2): 70-75, 2017 12 09.
Article in English | MEDLINE | ID: mdl-29054412

ABSTRACT

Many critical metabolic functions in the brain require adequate and timely delivery of iron. However, most studies when considering brain iron uptake have ignored the iron requirements of the endothelial cells that form the blood-brain barrier (BBB). Moreover, current models of BBB iron transport do not address regional regulation of brain iron uptake or how neurons, when adapting to metabolic demands, can acquire more iron. In this study, we demonstrate that both iron-poor transferrin (apo-Tf) and the iron chelator, deferoxamine, stimulate release of iron from iron-loaded endothelial cells in an in vitro BBB model. The role of the endosomal divalent metal transporter 1 (DMT1) in BBB iron acquisition and transport has been questioned. Here, we show that inhibition of DMT1 alters the transport of iron and Tf across the endothelial cells. These data support an endosome-mediated model of Tf-bound iron uptake into the brain and identifies mechanisms for local regional regulation of brain iron uptake. Moreover, our data provide an explanation for the disparity in the ratio of Tf to iron transport into the brain that has confounded the field.


Subject(s)
Blood-Brain Barrier/metabolism , Iron/metabolism , Animals , Biological Transport, Active/drug effects , Blood-Brain Barrier/drug effects , Brain/blood supply , Brain/metabolism , Cation Transport Proteins/antagonists & inhibitors , Cation Transport Proteins/metabolism , Cattle , Cells, Cultured , Endosomes/metabolism , Endothelial Cells/metabolism , Hepcidins/metabolism , Microvessels/metabolism , Models, Neurological , Transferrin/metabolism
4.
Biometals ; 29(4): 573-91, 2016 08.
Article in English | MEDLINE | ID: mdl-27457588

ABSTRACT

Iron is an essential element for human development. It is a major requirement for cellular processes such as oxygen transport, energy metabolism, neurotransmitter synthesis, and myelin synthesis. Despite its crucial role in these processes, iron in the ferric form can also produce toxic reactive oxygen species. The duality of iron's function highlights the importance of maintaining a strict balance of iron levels in the body. As a result, organisms have developed elegant mechanisms of iron uptake, transport, and storage. This review will focus on the mechanisms that have evolved at physiological barriers, such as the intestine, the placenta, and the blood-brain barrier (BBB), where iron must be transported. Much has been written about the processes for iron transport across the intestine and the placenta, but less is known about iron transport mechanisms at the BBB. In this review, we compare the established pathways at the intestine and the placenta as well as describe what is currently known about iron transport at the BBB and how brain iron uptake correlates with processes at these other physiological barriers.


Subject(s)
Blood-Brain Barrier/metabolism , Iron/metabolism , Animals , Biological Transport , Humans
5.
Neuro Oncol ; 18(5): 691-9, 2016 05.
Article in English | MEDLINE | ID: mdl-26519740

ABSTRACT

BACKGROUND: Detection of glioma with MRI contrast agent is limited to cases in which the blood-brain barrier (BBB) is compromised as contrast agents cannot cross the BBB. Thus, an early-stage infiltrating tumor is not detectable. Interleukin-13 receptor alpha 2 (IL-13Rα2), which has been shown to be overexpressed in glioma, can be used as a target moiety. We hypothesized that liposomes conjugated with IL-13 and encapsulating MRI contrast agent are capable of passing through an intact BBB and producing MRI contrast with greater sensitivity. METHODS: The targeted MRI contrast agent was created by encapsulating Magnevist (Gd-DTPA) into liposomes conjugated with IL-13 and characterized by particle size distribution, cytotoxicity, and MRI relaxivity. MR image intensity was evaluated in the brain in normal mice post injection of Gd-DTPA and IL-13-liposome-Gd-DTPA one day apart. The specificity for glioma detection by IL-13-liposome-Gd-DTPA was demonstrated in an intracranial glioma mouse model and validated histologically. RESULTS: The average size of IL-13-liposome-Gd-DTPA was 137 ± 43 nm with relaxivity of 4.0 ± 0.4 L/mmole-s at 7 Tesla. No significant cytotoxicity was observed with MTS assay and serum chemistry in mice. The MRI signal intensity was enhanced up to 15% post injection of IL-13-liposome-Gd-DTPA in normal brain tissue following a similar time course as that for the pituitary gland outside of the BBB. MRI enhanced by IL-13-liposome-Gd-DTPA detected small tumor masses in addition to those seen with Magnevist-enhanced MRI. CONCLUSIONS: IL-13-liposome-Gd-DTPA is able to pass through the uncompromised BBB and detect an early stage glioma that cannot be seen with conventional contrast-enhanced MRI.


Subject(s)
Brain Neoplasms/diagnostic imaging , Contrast Media/pharmacology , Gadolinium DTPA/pharmacology , Glioma/diagnostic imaging , Interleukin-13/pharmacology , Animals , Blood-Brain Barrier/drug effects , Disease Models, Animal , Liposomes/pharmacology , Magnetic Resonance Imaging/methods , Mice
SELECTION OF CITATIONS
SEARCH DETAIL
...